| Item Type | Name |
|
Concept
|
Dose-Response Relationship, Drug
|
|
Academic Article
|
Phase I study of amonafide dosing based on acetylator phenotype.
|
|
Academic Article
|
A phase I study of subcutaneous recombinant interleukin-2 and interferon alfa-2a.
|
|
Academic Article
|
Phase I clinical and pharmacology study of 502U83 given as a 24-h continuous intravenous infusion.
|
|
Academic Article
|
Model-guided determination of maximum tolerated dose in phase I clinical trials: evidence for increased precision.
|
|
Academic Article
|
Individualizing dosing of cancer chemotherapy.
|
|
Academic Article
|
New phase I trial methodology.
|
|
Academic Article
|
Phase I study of ZD9331 on short daily intravenous bolus infusion for 5 days every 3 weeks with fixed dosing recommendations.
|
|
Academic Article
|
Chronic daily low dose of 4-methyl-5-(2-pyrazinyl)-1,2-dithiole-3-thione (Oltipraz) in patients with previously resected colon polyps and first degree female relatives of breast cancer patients.
|
|
Academic Article
|
Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and LeukemiaGroup B study.
|
|
Academic Article
|
Estimation of the effect of food on the disposition of oral 5-fluorouracil in combination with eniluracil.
|
|
Academic Article
|
Determination of the optimal modulatory dose of O6-benzylguanine in patients with surgically resectable tumors.
|
|
Academic Article
|
Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480.
|
|
Academic Article
|
Phase I study of pegylated liposomal doxorubicin, paclitaxel, and cisplatin in patients with advanced solid tumors.
|
|
Academic Article
|
Five-day infusion of fluorodeoxyuridine with high-dose oral leucovorin: a phase I study.
|
|
Academic Article
|
Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer.
|
|
Academic Article
|
Serum soluble interleukin-2 receptor is associated with clinical and pathologic disease status in hairy cell leukemia.
|
|
Academic Article
|
Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer.
|
|
Academic Article
|
Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide.
|
|
Academic Article
|
Estimation of the glomerular filtration rate in cancer patients: a new formula for new drugs.
|
|
Academic Article
|
Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors.
|
|
Academic Article
|
Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients.
|
|
Academic Article
|
A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors.
|
|
Academic Article
|
Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies.
|
|
Academic Article
|
A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine.
|
|
Academic Article
|
Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study.
|
|
Academic Article
|
Effects of ketoconazole on glucuronidation by UDP-glucuronosyltransferase enzymes.
|
|
Academic Article
|
Finding the right dose.
|
|
Academic Article
|
Phase I study of inhaled Doxorubicin for patients with metastatic tumors to the lungs.
|
|
Academic Article
|
Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor.
|
|
Academic Article
|
R(+)XK469 inhibits hydroxylation of S-warfarin by CYP2C9.
|
|
Academic Article
|
Pharmacodynamic genes do not influence risk of neutropenia in cancer patients treated with moderately high-dose irinotecan.
|
|
Academic Article
|
Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity.
|
|
Academic Article
|
Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer.
|
|
Academic Article
|
Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101.
|
|
Academic Article
|
Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics and pharmacodynamics in women with solid tumors: Cancer and Leukemia Group B Study 9763.
|
|
Academic Article
|
Correspondence re: Xiu F. Hu et al., Combined use of cyclosporin A and verapamil in modulating multidrug resistance in human leukemia cell lines. Cancer Res., 50: 2953-2957, 1990.
|
|
Academic Article
|
Encephalopathy is the dose-limiting toxicity of intravenous hepsulfam: results of a phase I trial in patients with advanced hematological malignancies.
|
|
Academic Article
|
Phase I trial of a genetically engineered interleukin-2 fusion toxin (DAB486IL-2) as a 6 hour intravenous infusion in patients with hematologic malignancies.
|
|
Academic Article
|
Individualizing dosing of irinotecan.
|
|
Academic Article
|
Dose-escalation models for combination phase I trials in oncology.
|
|
Academic Article
|
Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer.
|
|
Academic Article
|
Body surface area as a determinant of pharmacokinetics and drug dosing.
|
|
Academic Article
|
Phase 1 dose escalation study of docetaxel with filgrastim support in patients with advanced solid tumors.
|
|
Academic Article
|
Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leucovorin in patients with organ dysfunction.
|
|
Academic Article
|
Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480.
|
|
Academic Article
|
A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital.
|
|
Academic Article
|
Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies.
|
|
Academic Article
|
A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia.
|
|
Academic Article
|
Opportunities and challenges in the development of experimental drug combinations for cancer.
|
|
Academic Article
|
Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea.
|
|
Academic Article
|
Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies.
|
|
Academic Article
|
Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer.
|
|
Academic Article
|
A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia.
|
|
Academic Article
|
Conventional dosing of anticancer agents: precisely wrong or just inaccurate?
|
|
Academic Article
|
First-in-human phase I study of Lurbinectedin (PM01183) in patients with advanced solid tumors.
|
|
Academic Article
|
Taking a Measured Approach to Toxicity Data in Phase I Oncology Clinical Trials.
|
|
Academic Article
|
Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance).
|
|
Academic Article
|
Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer.
|
|
Academic Article
|
Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial.
|
|
Academic Article
|
A Cost-Focused Alternative Cancer Medication Dispensing Strategy-"Pack Splitting".
|
|
Academic Article
|
Applied Clinical Pharmacology in a Crisis: Interleukin-6 Axis Blockade and COVID-19.
|
|
Academic Article
|
COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia.
|
|
Academic Article
|
Pharmacokinetic Simulation Analysis of Less Frequent Nivolumab and Pembrolizumab Dosing: Pharmacoeconomic Rationale for Dose Deescalation.
|
|
Academic Article
|
Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study.
|
|
Academic Article
|
Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022.
|